Darifenacin has 21 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Darifenacin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 21
- Major
- 6
- Moderate
- 12
- Minor
- 2
Major (6)
- Darifenacin + Clarithromycin— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
- Darifenacin + Itraconazole— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
- Darifenacin + Ketoconazole— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
- Darifenacin + Nefazodone— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
- Darifenacin + Nelfinavir— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
- Darifenacin + Ritonavir— Darifenacin systemic exposure is increased with potent CYP3A4 inhibitors; daily dose should not exceed 7.5 mg when co-ad…
Moderate (12)
- Darifenacin + Acidifying Agents— Concomitant use may increase frequency and/or severity of anticholinergic effects (dry mouth, constipation, blurred visi…
- Darifenacin + Deferasirox— Deferasirox may induce CYP3A4 resulting in decreased darifenacin concentration. Monitor for reduced effectiveness.
- Darifenacin + Diltiazem— Moderate CYP3A4 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with diltiazem.
- Darifenacin + Duloxetine— CYP2D6 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with duloxetine.
- Darifenacin + Erythromycin— No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconaz…
- Darifenacin + Flecainide— Darifenacin may increase flecainide exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution shou…
- Darifenacin + Fluconazole— No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconaz…
- Darifenacin + Fluoxetine— CYP2D6 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with fluoxetine.
- Darifenacin + Paroxetine— CYP2D6 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with paroxetine.
- Darifenacin + Quinidine— CYP2D6 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with quinidine.
- Darifenacin + Thioridazine— Darifenacin may increase thioridazine exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution sh…
- Darifenacin + Verapamil— Moderate CYP3A4 inhibitor; no dosing adjustments recommended for darifenacin when co-administered with verapamil.
Minor (2)
- Darifenacin + Digoxin— Darifenacin did not have clinically relevant effect on digoxin pharmacokinetics; routine therapeutic monitoring should b…
- Darifenacin + Warfarin— Darifenacin had no significant effect on prothrombin time; standard therapeutic monitoring should be continued.